Syngenta is currently developing VipCot™, a transgenic insect-resistant cotton that expresses both Vip3A and Cry1Ab toxins. The mode-of-action of Vip3A is different from that of Cry1Ab, and there is no cross-resistance between Vip3A and Cry toxins, so that a stack of Vip3A and Cry1Ab will represent an excellent product from the Insect Resistance Management (IRM) perspective. We are currently evaluating the high dose status of VipCot™ to support the IRM strategy that we will propose for the product. In this paper, data from two laboratory-based methods assessing the high dose status of VipCot™ are presented.